Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain Results from the National Heart, Lung, and Blood Institute women's ischemia syndrome evaluation study by Arant, Christopher B et al.
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OBJECTIVES This study was designed to investigate the relationship between hemoglobin level (Hgb) and
adverse cardiovascular outcomes in women with suspected ischemia.
BACKGROUND Low Hgb levels correlate with increased cardiovascular morbidity and mortality in patients
presenting with acute myocardial infarction (MI) or congestive heart failure (CHF).
However, the prognostic significance of Hgb in women with suspected ischemia is unclear.
METHODS As part of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s
Ischemia Syndrome Evaluation (WISE), we prospectively studied 936 women referred for
coronary angiography to evaluate suspected ischemia. We compared Hgb levels with
cardiovascular risk factors, core lab interpreted angiograms, inflammatory markers, and
adverse cardiovascular outcomes.
RESULTS Of women enrolled, 864 (mean age 58.4 11.6 years) had complete Hgb, angiogram, and
follow-up (mean 3.3  1.7 years) data. The mean Hgb was 12.9 g/dl (range 7.7 to 16.4
g/dl) and 184 women (21%) were anemic (Hgb 12 g/dl). Anemic women had higher
creatinine and were more likely to be nonwhite and have a history of diabetes, hypertension, and
CHF (p  0.05). However, we found no difference in EF or severity of coronary artery
disease. Anemic women had a higher risk of death from any cause (10.3% vs. 5.4%; p 0.02)
and total adverse outcomes (26% vs. 16%, p  0.01). In a multivariable model, decreasing
Hgb was associated with significantly higher risk of adverse outcomes (hazard ratio  1.20,
p  0.002). Also, anemic women had shorter survival time free of adverse outcome (p 
0.001).
CONCLUSIONS Our findings extend previous reports, linking lower hemoglobin levels with higher risk for
adverse cardiovascular outcomes, to women evaluated for suspected ischemia in the absence
of acute MI or CHF. (J Am Coll Cardiol 2004;43:2009–14) © 2004 by the American
College of Cardiology Foundations
w
D
p
c
w
r
d
p
a
s
s
i
d
m
s
ischemia-related chest pain is due to an imbalance between
yocardial oxygen supply and demand, primarily related to
picardial coronary flow limitations caused by atherosclero-
is. In patients without significant epicardial coronary artery
bstruction, endothelial and/or microvascular dysfunction
lso have the potential to limit blood flow and have been
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Manuscript received September 30, 2003; revised manuscript received Decembera3, 2003, accepted January 19, 2004.uggested as an underlying mechanism for chest pain in
omen with angiographically normal coronary arteries (1).
ecreased hemoglobin levels (Hgb) with subsequent im-
aired oxygen-carrying capacity in the setting of limited
oronary flow by either mechanism have the potential to
orsen ischemia and associated symptoms. Furthermore,
ecent research suggests that decreased Hgb is an indepen-
ent predictor of increased morbidity and mortality in
atients presenting with acute myocardial infarction (MI)
nd patients with hematocrit 33% who received transfu-
ions had improved outcomes (2–4). In addition, several
tudies in patients with heart failure (HF) primarily from
schemic heart disease showed that anemia was indepen-
ently associated with worsened symptoms and increased
orbidity and mortality (5–7). Also, smaller studies have
hown that treating anemia in patients undergoing dialysis
s associated with regression of left ventricular dysfunction
nd improved outcomes (8–10). Table 1 summarizes some
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Anemia Predicts Outcomes in Women With Chest Pain June 2, 2004:2009–14f the studies evaluating the relationship between anemia
nd cardiovascular disease.
The National Center for Health Statistics reported that
pproximately 3.4 million Americans have anemia, with a
uch higher prevalence in women than in men (11).
lthough anemia is a well-known inciter of myocardial
schemia in patients with cardiovascular disease and seems
o contribute to increased mortality and morbidity in pa-
ients with acute MI or HF, the prognostic importance of
ecreased hemoglobin in women presenting for evaluation
f chest pain has not been studied. The aim of our study was
o determine the impact of hemoglobin level on the adverse
utcomes of women enrolled in the Women’s Ischemia
yndrome Evaluation (WISE).
ETHODS
he WISE study, a National Heart, Lung, and Blood
nstitute (NHLBI)-sponsored four-center study, aims to
mprove diagnostic testing in the evaluation of ischemic
eart disease in women. Between 1996 and 2000, 936
omen age 18 to 83 years were enrolled. The institutional
eview board at each site approved the study, and all data
ere monitored by an independent Data and Safety Mon-
toring Committee appointed by the NHLBI. Participant
onsent was obtained. Women referred for clinically indi-
ated angiograms to further evaluate the basis for suspected
schemia were included in the study. Major exclusion
Abbreviations and Acronyms
CAD  coronary artery disease
CHF  congestive heart failure
EF  ejection fraction
HF  heart failure
Hgb  hemoglobin
hs-CRP  high sensitivity C-reactive protein
IL  interleukin
MI  myocardial infarction
TNF  tumor necrosis factor
WISE  Women’s Ischemia Syndrome Evaluation
study
able 1. Summary of Studies Evaluating Anemia and Cardiovasc
Patient Condition n
eneral population (2) 14,410 (57% women)
ospitalized for acute MI (3) 78,974 (54% women)
eft ventricular dysfunction (5) 6,635 (14% women)
dvanced heart failure (6) 1,061 (23% women)
ew onset heart failure (7) 12,065 (51% women)
enal failure requiring dialysis (8) 100 (46% women)
enal failure requiring dialysis (9) 22
dvanced heart failure (10) 40V  cardiovascular; Hct  hematocrit; MI  myocardial infarction.riteria for the WISE study were comorbidity that would
ompromise one-year follow-up, pregnancy, contraindica-
ions to provocative diagnostic testing, cardiomyopathy,
ew York Heart Association functional class III to IV
ongestive heart failure (CHF), recent MI, significant
alvular or congenital heart disease, and a language barrier
o questionnaire testing. Details of the protocol and design
f the WISE study are published elsewhere (12).
Baseline evaluation included a physical examination and
ollection of clinical and laboratory data (Table 2). Quali-
ative and quantitative coronary angiographic analyses were
arried out by core lab according to methodology published
rom the WISE study (12,13). Severity of coronary artery
isease (CAD) was determined by angiographic assessment
f luminal diameter narrowing. Obstructive CAD was
efined as 50% reduction, minimal as 20% to 49%
eduction, and no stenosis as 20% reduction of luminal
iameter. A CAD severity score was defined as an aggregate
f percent luminal stenosis, extent and location of stenosis,
nd degree of collateral vessels. Hemoglobin levels were
nalyzed on site, and anemia was defined using World
ealth Organization criteria of Hgb 12 g/dl (14). Other
omponents of the complete blood count were not recorded.
tandardized forms containing demographic, clinical, an-
iographic, and follow-up information were collected at the
ite and then sent to the WISE study data coordinating
enter in Pittsburgh for processing.
An experienced nurse and/or physician collected
ollow-up data in person or by telephone interview at six
eeks and then yearly. Each woman was queried for the
ccurrence of adverse outcomes. When an adverse outcome
as identified, the referring physician was contacted for
onfirmation, dates, and documentation. In the event of
eath, a death certificate was obtained and an event com-
ittee reviewed available information to determine the
ikelihood of a cardiovascular etiology.
Measurements of inflammatory markers were available in
02 women and analyzed at a core lab. Measurement of
hese markers was added to the project after recruitment had
egun, so previously enrolled patients did not have adequate
tored serum to measure these levels. Plasma sampled at
Disease
Results
ia was a risk factor for MI, revascularization, or CV death
MI, patients with lower Hct had a higher 30-day mortality
ired kidney function and anemia were risk factors for increased mortality
ia was associated with worsened functional status and was independent
dictor of mortality
ia was an independent risk factor for mortality
ed that regression of left ventricular wall mass was possible with optimal
nagement, including correction of anemia
ing anemia with recombinant erythropoietin (epo) was associated with
tial regression of ventricular hypertrophy
ction of anemia with epo and iron was associated with improved cardiac
ction, decreased hospitalizations and stabilization of renal functionular
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June 2, 2004:2009–14 Anemia Predicts Outcomes in Women With Chest Painaseline was frozen at 70°C for subsequent measurement
f inflammatory markers. Levels of high-sensitivity
-reactive protein (hs-CRP) were measured by a high-
ensitivity method using validated techniques (15). Inter-
eukin (IL)-6 and tumor necrosis factor (TNF)-alpha levels
ere measured from plasma using a commercially available
nzyme-linked immunosorbent assay kit.
The primary analysis focused on adverse outcome, defined
s a composite of hospitalization for nonfatal MI, CHF,
troke, other vascular events, or death. Myocardial infarction
as defined by creatine kinase-MB isoenzyme elevation at
east five times the upper limit of normal. Other vascular events
ncluded primarily peripheral atherosclerosis-related events.
tatistical analyses. Data are summarized as mean and
tandard deviation for continuous variables and frequencies
Table 2. Baseline Characteristics
All
Age (yrs)
Total cholesterol (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Fasting blood sugar (mg/dl)
Creatinine (mg/dl)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Pulse (beats/min)
BMI (kg/m2)
Waist circumference (in)
Waist hip ratio
CAD severity score
Ejection fraction (%)
Nonwhite
More than high school education
History of diabetes
Diabetes, using insulin
History of dyslipidemia
Current smoking
History of hypertension
History of congestive heart failure
Family history of premature CAD
Postmenopausal
S/P hysterectomy
Current HRT (postmenopausal only)
Obese (BMI 30)
Angiographic CAD stenosis 50%
Angiographic CAD stenosis 20% to 49%
Medication Use
ACE inhibitors
Aspirin
Beta-blockers
Statins
Thyroid medication
ACE  angiotensin-converting enzyme; BMI  body mas
lipoprotein; HRT  hormone replacement therapy; HS  hor categorical variables. Tests for normality were performed ising the Shapiro-Wilk test. Comparisons of characteristics
f women with anemia (hemoglobin levels 12 g/dl) and
hose without anemia were done by Wilcoxon tests for
ontinuous variables and chi-square tests for discrete data.
pearman rank correlations coefficients were used to assess
elationships between hemoglobin values and severity scores
s well as hemoglobin values and inflammatory markers.
oronary artery disease is defined as a categorical variable
obstructive CAD/no obstructive CAD) and as a continu-
us variable called the severity score. Because the CAD
everity score, ejection fraction (EF), and creatinine do not
ollow a normal distribution (Shapiro-Wilk test), the Wil-
oxon test was used to compare values of women with
nemia and those without anemia. A general linear model
as used to assess relationships between hemoglobin and
en (n  864)
Women With Inflammatory
Marker Levels (n  602)
Mean  SD
4  11.6 58.0  11.7
4  45 191  43
4  13 53  12
1  39 109  37
5  123 154  130
7  55 115  54
9  0.5 0.9  0.5
7  22 137  22
7  11 76  11
4  13 74  13
7  6.6 29.7  6.9
8  7.3 36.5  7.3
5  0.11 0.87  0.11
0  14.8 13.7  13.3
2  10.8 65.3  10.8
Percent With Characteristic
18.8 18.1
38.4 39.7
25.2 25.6
47.7 43.5
54.7 54.5
20.2 19.8
59.6 57.6
8.6 8.3
66.4 65.9
75.9 74.9
53.7 53.4
46.0 48.4
41.7 41.3
39.2 35.1
24.7 24.9
Percent Reporting Use
26.4 26.3
60.6 60.5
39.5 40.9
25.0 27.4
13.9 15.0
x; CAD  coronary artery disease; HDL  high-density
hool; LDL  low-density lipoprotein; S/P  status post.Wom
58.
19
5
11
15
11
0.
13
7
7
29.
36.
0.8
15.
65.
s indenflammatory markers while adjusting for variables found to
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Anemia Predicts Outcomes in Women With Chest Pain June 2, 2004:2009–14e significantly different between the cohort of women with
nflammatory markers and those without. In these analyses,
log transformation of the inflammatory markers was used.
nivariate and multivariable Cox regression models were
sed to identify predictors of mortality and adverse out-
omes. Variables were chosen for entry into the model based
n previous univariate associations. Multivariable Cox re-
ression models were run as a forward step selection
rocedure. For the Cox proportional hazards model, the
azard ratio and 95% confidence intervals were calculated.
he Kaplan-Meier method was used to estimate cumulative
ncidence rates of adverse events, with the log-rank statistic
sed to assess differences by level of hemoglobin. Adjusted
stimates of event-free survival were based on the Cox
odel. All tests were two-sided and values of p 0.05 were
onsidered statistically significant. All statistics were ana-
yzed using SAS version 8.2 (Cary, North Carolina).
ESULTS
aseline clinical characteristics. Of 936 women enrolled
n the WISE, 864 (mean age 58.4  11.6 years) had
omplete data (Table 2). They were followed prospectively
or a mean of 3.3  1.7 years (2,831 patient-years) after
ntry. Baseline characteristics reveal that 60% had a history
f hypertension, 55% dyslipidemia, 25% diabetes, 20%
urrently smoking, and 60% with a family history of
remature heart disease. Of the women enrolled, 19% were
on-white. Only 184 (21%) women were anemic (Hgb12
/dl). Despite the high proportion of women with tradi-
ional CAD risk factors, only 39% had any coronary
therosclerotic stenoses 50% diameter reduction by an-
iography, and 64% had any stenoses 20%. We found no
orrelation between Hgb level and presence of or severity of
oronary atherosclerosis. The mean EF was 65.2  11%,
nd 3% had an EF 40%.
linical outcomes. Over the follow-up period, 155 (18%)
omen had an adverse outcome. Thirty-five had more than
ne event. Fifty-six women died, with 29 (52%) of these
eaths cardiovascular in etiology. Of 184 women with
nemia, 11 (6%) had a cardiovascular-related death com-
ared with 18 (2.6%) of 680 non-anemic women (p 
.03). Anemic women had a significantly higher rate of first
dverse outcome (Fig. 1) (p 0.001), risk of death from any
ause (10.3% vs. 5.4%, p  0.02), and total adverse
utcomes (26% vs. 16%, p  0.01). Furthermore, anemic
omen were more likely to be non-white and to have a
istory of diabetes mellitus, hypertension, CHF, and cur-
ently not smoking (all p  0.01). However, we found no
ifference in EF (66% vs. 64%, p  NS) or the presence or
everity of CAD in anemic compared to non-anemic
omen. Anemic women did have a significantly higher
reatinine level (mean 1.1 vs. 0.8 mg/dl, p  0.01).
therwise, we found no significant difference between
nemic and non-anemic women regarding other character-
stics and risk factors. cOn univariate analysis, each g/dl decrease in Hgb was
ssociated with a 27% increase in all-cause mortality (hazard
atio  1.27, p  0.01). Also on univariate analyses, age,
iabetes, dyslipidemia, hypertension, creatinine, use of sta-
ins, and any CAD stenosis20% diameter narrowing were
ach associated with adverse outcomes. In a multivariable
ox model, a lower Hgb level was associated with signifi-
antly higher risk of adverse outcomes (hazard ratio  1.20,
 0.002). Therefore, a decrease in Hgb of only 1 g/dl was
ssociated with a 20% increase in adverse outcomes. Fur-
hermore, after controlling for factors thought to contribute
o or confound the observed deleterious effects of anemia on
ardiovascular disease, Hgb independently predicted adverse
utcomes. Figure 2 shows the significant independent
redictors of adverse outcomes from Cox multivariable
odel.
Serum inflammatory markers, including hs-CRP, IL-6,
nd TNF-alpha, were available in 64% of the women (Table
). When compared with women without inflammatory
igure 1. Adjusted estimate of survival free from adverse outcomes by level
f hemoglobin (Hgb). Survival curves were generated using Kaplan-Meier
ethods. See text for definition of adverse outcomes. Note the decreased
urvival free from adverse outcomes for women with anemia.
igure 2. Risk factors found to be significant with hazard ratios (HR)
ndependent predictor of any adverse outcome in multivariate analysis, and
5% confidence intervals (CI) for any adverse outcome. Hemoglobin is
odeled as a continuous variable. Note the significantly increased risk of
dverse outcomes associated with decreased hemoglobin levels. CAD 
oronary artery disease.
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June 2, 2004:2009–14 Anemia Predicts Outcomes in Women With Chest Paineasurements, women with inflammatory marker measure-
ents had lower waist:hip ratio (mean 0.85 vs. 0.87, p 
.002), greater statin use (27% vs. 19%, p  0.01), lower
AD severity score (mean 13.7 vs. 17.7, p  0.002), and
ower prevalence of any CAD stenosis 50% (35% vs. 49%,
 0.001). Anemic women had higher levels of CRP (p 
.02), IL-6 (p 0.001), and TNF-alpha (p 0.006). After
djusting for the differences in variables listed above, anemia
as associated with increased levels of CRP (p  0.07),
L-6 (p  0.001), and TNF-alpha (p  0.005).
ISCUSSION
n association between hemoglobin level and ischemic
eart disease in women has not been well recognized. We
ound that hemoglobin level was an independent predictor
f adverse outcomes in women presenting with suspected
schemia. Our study primarily found that women with lower
emoglobin levels had higher risk of adverse outcomes. In
ddition, the all-cause and cardiovascular mortality of
omen with anemia was significantly increased. Further-
ore, differences in traditional risk factors, CAD, renal
mpairment, thyroid disease, and cardiovascular medication
se did not account for the differences observed in adverse
utcomes. In multivariable analysis, decreased hemoglobin
as also a stronger predictor of adverse outcomes than many
raditional cardiovascular risk factors such as increasing age,
istory of hypertension, current smoking, and family his-
ory. Despite the univariate association, multivariable anal-
sis did not show a significant independent relationship
etween statin use and adverse outcomes. Epicardial CAD
nd a history of diabetes were the only variables that were
tronger predictors of adverse outcomes in this group of
omen.
We also found that women with anemia had significantly
igher levels of inflammatory markers. Even after adjusting
or variables known to decrease or be associated with these
arkers, anemia remained inversely related to inflammatory
arker levels. Furthermore, women without inflammatory
arker measurements had a higher waist:hip ratio, less
tatin use, and more severe CAD than the women with
arker measurements. Therefore, women without inflam-
atory marker measurements could have higher levels of
hese markers, making it possible that we are underestimat-
ng the association between hemoglobin level and inflam-
atory marker levels in this population.
The basis for a link between hemoglobin level and
dverse cardiovascular events in these women is not known.
istorically, explanations for anemia-related cardiovascular
ysfunction have included left ventricular dilation with
emodeling as well as an increase in cardiac output through
arious mechanisms such as decreased blood viscosity,
ypoxia-induced vasodilation, or altered nitric oxide activity
ith subsequent development of cardiac failure (16,17).
lthough compensated HF cannot be completely excludeds a contributor to the adverse outcomes seen in this study, pF was not significantly associated with hemoglobin level or
ith risk of adverse outcome. In addition, 3% of patients
ad an EF 40%.
A possible link could be the relationship of inflammation
o both anemia and cardiovascular disease. Although the
tiology of low hemoglobin levels could not be determined
rom the data available in our study, epidemiologic studies
ave shown that anemia in older men and women is most
ikely secondary to anemia of chronic disease or iron
eficiency anemia (18). In this study, 76% of the patients
ere postmenopausal and thus less likely to have iron
eficiency due to menorrhagia. Anemia of chronic disease is
ssociated with chronic inflammatory states and the effects
f various cytokines, such as TNF, ILs, and interferons,
hich are also known to be associated with vascular disease
nd death (19). These inflammatory mediators may play a
ole in the lower hemoglobin levels, coronary microvascular
ysfunction, and adverse outcomes seen in this population
f women (1). In addition, 20% of the anemic women were
onwhite. Some women with anemia and adverse events
ay have a form of occult hemoglobinopathy, which may be
ssociated with impaired delivery and metabolism of nitric
xide leading to coronary vascular dysfunction (20).
In contrast to previous studies (2–7), the adverse event
ates in this study were significantly increased even in
omen with only mild to moderate decreases in hemoglobin
evel. Several studies have shown that correcting anemia
mproves outcomes (3,8–10,21), but previous analyses of
nemia are primarily limited to patients with MI or HF or
atients requiring hemodialysis. To our knowledge, no
tudies have been published regarding anemia in men
valuated for suspected ischemia without HF or MI. Be-
ause of the known differences between men and women,
ncluding genotype, hormones, and delays in manifestations
f ischemic heart disease, extending our findings to a similar
opulation of men would be speculative. In addition,
omen 18 years of age and older were enrolled with signs or
ymptoms warranting invasive investigation for suspected
schemia. This resulted in a population of women with a
ean age of 58 years. This and further analyses of the
ISE study cohort outcomes may show that the age or
ther characteristics of women at risk for ischemic heart
isease are different from our current perceptions.
tudy limitations. This prospective observational study
as the inherent limitations of such a design. In addition,
his study also has a relatively small population of women
ith Hgb levels measured only at baseline and without other
ed blood cell indices or serum iron studies available that
ay help determine the etiology of anemia. Correction of
nemia at follow-up was also not captured by our database;
hus, we are unable to determine the duration of anemia or
he effect of changes in hemoglobin or treatment on
utcomes. Finally, women may have been lost to follow-up
s a result of an adverse event (e.g., survival bias); therefore,
n underestimation of the long-term adverse events rates is
ossible.
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Anemia Predicts Outcomes in Women With Chest Pain June 2, 2004:2009–14onclusions. Our findings suggest that lower Hgb is
ignificantly and independently associated with adverse
ardiovascular outcomes in women presenting with
schemic-type symptoms, regardless of the presence or
everity of CAD. Furthermore, this association is seen with
nly modest reductions in Hgb during intermediate-term
ollow-up. These results extend previous reports linking
ower Hgb with higher risk for adverse cardiovascular
utcomes to women evaluated for suspected ischemia in the
bsence of acute MI or CHF.
The prevalence and prognostic importance of Hgb levels
n this population necessitate further confirmation and
nvestigation of the underlying pathophysiologic mecha-
isms as well as the potential benefits of therapeutic
ntervention in women with low Hgb being evaluated for
uspected ischemia. Further thought should also be given to
he clinical relevance of the current definition of anemia in
his population, and further recognition of clinically impor-
ant hemoglobin levels should be based on well-designed
esearch of clinical and epidemiologic outcomes.
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